In chronic myeloid leukaemia (CML), the level of cells with the BCR‐ABL rearrangement is widely used to characterize the disease progression, and decreases after imatinib treatment. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.